Standard weight loss, whether by caloric deficit or GLP-1 therapy, typically follows a 70/30 ratio (70% fat loss, 30% lean mass/muscle loss)
Obesity pharmacotherapy, such as GLP-1 receptor agonists, is often necessary for long-term weight management, and stopping these medications frequently results in weight regain
Medications approved for diabetes management (e.g., Ozempic, Mounjaro) may be covered when prescribed for FDA-approved diabetic indications, subject to medical necessity review." This creates the paradox: semaglutide 1.0 mg (Ozempic) for diabetes is covered
This synergistic approach not only accelerates your weight loss but also supports your overall health and well-being
Constipation: Less commonly, constipation can occur as the digestive system adjusts to slower gastric emptying